Company: INGN
Filing Date: 2025-01-27
Form Type: 8-K
Source: 0000950170-25-008986
Chunk: 0

Company: Inogen Inc
Filing Date: 2025-01-27
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

Collaboration Agreement

On January 25, 2025, Inogen, Inc., a Delaware corporation (the “ Company” or “ Inogen”), entered into a Strategic Collaboration Agreement (the “ Collaboration Agreement”) with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (“ Yuwell”). The collaboration with Yuwell is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R& D collaboration, and accelerate the entry of Inogen's brand into the Chinese market. The Collaboration Agreement will establish guidelines and principles relating to the parties' cooperation with respect to distribution, research and development, licensing, and supply chain optimization. The parties have also entered into two distribution arrangements whereby Inogen will distribute certain products supplied by Yuwell in the United States and specified European countries and Yuwell will distribute certain products supplied by Inogen in specified Asia Pacific countries.

Securities Purchase Agreement

Concurrently with the execution of the Collaboration Agreement, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement”) with Yuwell (Hong Kong) Holdings Limited, a wholly-owned subsidiary of Yuwell (the “ Investor”), pursuant to which the Investor will purchase 2,626,425 shares (the “ Shares”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock”), at a price per share of $10.36, for an aggregate purchase price of approximately $27.2 million (the “ Private Placement”). The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Investor, on the other hand, and customary conditions to closing. The closing of the Private Placement is expected to occur during the first quarter of 2025.

Registration Rights Agreement

Concurrently with the closing of the Private Placement, the Company will enter into a Registration Rights Agreement (the “ Registration Rights Agreement”) with the Investor, which provides that the Investor will have the right, beginning on the 180th calendar day following the date of the Registration Rights Agreement, to cause the Company to register the resale of the Shares issued to the Investor pursuant to the Purchase Agreement. The Company is required to prepare and file a registration statement with the Securities and Exchange Commission (the “ SEC”) as promptly as reasonably practicable and in any event no later than 30 calendar days after receiving a written request to do so from the Investor,